Floatz Rating
C36/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
21High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01284348CT.gov To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00931606CT.gov Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sotatercept (this asset) | Merck Sharp & Dohme LLC | P2 | C · 36 |
| Epoetin Alfa | Mayo Clinic | P4 | BBB |
| Erythropoietin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Epoetin Beta | Institut du Cancer de Montpellier - Val d'Aurelle | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | BBB |
| Darbepoetin Alfa | Amgen | P3 | BB |
| Cyclophosphamide | OHSU Knight Cancer Institute | P4 | BB |
| Ferric Cation | National Cancer Center, Korea | P4 | BB |
| Methoxy Polyethylene Glycol-Epoetin Beta | Taipei Veterans General Hospital, Taiwan | P4 | BB |
+42 more in the Anemia cohort
Other indications for Sotatercept
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P2 | C · 36 |
| Beta-Thalassemia Major | — | P2 | C · 36 |
| Beta-Thalassemia Intermedia | — | P2 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sotatercept in Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sotatercept-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →